Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1964 1
1967 1
1970 1
1971 1
1972 1
1973 1
1975 3
1976 4
1977 2
1978 1
1979 2
1980 3
1981 3
1982 5
1983 2
1984 1
1985 7
1986 4
1987 3
1988 8
1989 11
1990 12
1991 12
1992 12
1993 7
1994 21
1995 17
1996 12
1997 18
1998 17
1999 16
2000 15
2001 18
2002 25
2003 23
2004 17
2005 21
2006 22
2007 24
2008 24
2009 21
2010 16
2011 15
2012 15
2013 22
2014 25
2015 18
2016 18
2017 20
2018 17
2019 8
2020 12
2021 21
2022 8
2023 12
2024 11
2025 10

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

620 results

Results by year

Filters applied: . Clear all
Page 1
Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, Nelson ME, Wells PS, Gould MK, Dentali F, Crowther M, Kahn SR. Kearon C, et al. Chest. 2012 Feb;141(2 Suppl):e419S-e496S. doi: 10.1378/chest.11-2301. Chest. 2012. PMID: 22315268 Free PMC article.
METHODS: We generated strong (Grade 1) and weak (Grade 2) recommendations based on high-quality (Grade A), moderate-quality (Grade B), and low-quality (Grade C) evidence. RESULTS: For acute DVT or pulmonary embolism (PE), we recommend initial parenteral anticoagulan …
METHODS: We generated strong (Grade 1) and weak (Grade 2) recommendations based on high-quality (Grade A), moderate-quality (Grade B), and l …
Thrombolytic therapy for pulmonary embolism.
Zuo Z, Yue J, Dong BR, Wu T, Liu GJ, Hao Q. Zuo Z, et al. Cochrane Database Syst Rev. 2021 Apr 15;4(4):CD004437. doi: 10.1002/14651858.CD004437.pub6. Cochrane Database Syst Rev. 2021. PMID: 33857326 Free PMC article.
BACKGROUND: Thrombolytic therapy is usually reserved for people with clinically serious or massive pulmonary embolism (PE). ...More studies of high methodological quality are needed to assess safety and cost effectiveness of thrombolytic ther …
BACKGROUND: Thrombolytic therapy is usually reserved for people with clinically serious or massive pulmonary embolis …
Systemic thrombolytic therapy for acute pulmonary embolism: a systematic review and meta-analysis.
Marti C, John G, Konstantinides S, Combescure C, Sanchez O, Lankeit M, Meyer G, Perrier A. Marti C, et al. Eur Heart J. 2015 Mar 7;36(10):605-14. doi: 10.1093/eurheartj/ehu218. Epub 2014 Jun 10. Eur Heart J. 2015. PMID: 24917641 Free PMC article.
AIM: Thrombolytic therapy induces faster clot dissolution than anticoagulation in patients with acute pulmonary embolism (PE) but is associated with an increased risk of haemorrhage. ...Fifteen trials involving 2057 patients were included in our meta-a …
AIM: Thrombolytic therapy induces faster clot dissolution than anticoagulation in patients with acute pulmonary embo …
Acute Management of High-Risk and Intermediate-Risk Pulmonary Embolism in Children: A Review.
Ross C, Kumar R, Pelland-Marcotte MC, Mehta S, Kleinman ME, Thiagarajan RR, Ghbeis MB, VanderPluym CJ, Friedman KG, Porras D, Fynn-Thompson F, Goldhaber SZ, Brandão LR. Ross C, et al. Chest. 2022 Mar;161(3):791-802. doi: 10.1016/j.chest.2021.09.019. Epub 2021 Sep 26. Chest. 2022. PMID: 34587483 Free PMC article. Review.
Severe forms of pulmonary embolism (PE) in children, althought rare, cause significant morbidity and mortality. ...Pediatric emergency and intensive care physicians should be familiar with the risks and benefits of each therapy to expedite care. PE response t …
Severe forms of pulmonary embolism (PE) in children, althought rare, cause significant morbidity and mortality. ...Pediatric e …
Reduced-Dose Intravenous Thrombolysis for Acute Intermediate-High-risk Pulmonary Embolism: Rationale and Design of the Pulmonary Embolism International THrOmbolysis (PEITHO)-3 trial.
Sanchez O, Charles-Nelson A, Ageno W, Barco S, Binder H, Chatellier G, Duerschmied D, Empen K, Ferreira M, Girard P, Huisman MV, Jiménez D, Katsahian S, Kozak M, Lankeit M, Meneveau N, Pruszczyk P, Petris A, Righini M, Rosenkranz S, Schellong S, Stefanovic B, Verhamme P, de Wit K, Vicaut E, Zirlik A, Konstantinides SV, Meyer G; PEITHO-3 Investigators. Sanchez O, et al. Thromb Haemost. 2022 May;122(5):857-866. doi: 10.1055/a-1653-4699. Epub 2021 Oct 31. Thromb Haemost. 2022. PMID: 34560806 Free PMC article. Clinical Trial.
Intermediate-high-risk pulmonary embolism (PE) is characterized by right ventricular (RV) dysfunction and elevated circulating cardiac troponin levels despite apparent hemodynamic stability at presentation. ...Reduced-dose thrombolysis may be capable of improving sa …
Intermediate-high-risk pulmonary embolism (PE) is characterized by right ventricular (RV) dysfunction and elevated circulating …
Comparative Efficacy and Safety of Thrombolytic Agents for Pulmonary Embolism: A Bayesian Network Meta-Analysis.
Li HY, Wang YB, Ren XY, Wang J, Wang HS, Jin YH. Li HY, et al. Pharmacology. 2023;108(2):111-126. doi: 10.1159/000527668. Epub 2023 Jan 5. Pharmacology. 2023. PMID: 36603558 Free PMC article.
BACKGROUND: Thrombolytic agents and anticoagulants are the two classes of medication used in the treatment of acute pulmonary embolism (PE). ...RESULTS: A total of 29 RCTs (3,067 patients) were included, of which 6 studies (304 patients) were massive PE, 14 s …
BACKGROUND: Thrombolytic agents and anticoagulants are the two classes of medication used in the treatment of acute pulmonary …
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Geerts WH, et al. Chest. 2004 Sep;126(3 Suppl):338S-400S. doi: 10.1378/chest.126.3_suppl.338S. Chest. 2004. PMID: 15383478 Review.
This article discusses the prevention of venous thromboembolism (VTE) and is part of the Seventh American College of Chest Physicians Conference on Antithrombotic and Thrombolytic Therapy: Evidence-Based Guidelines. Grade 1 recommendations are strong and indicate th …
This article discusses the prevention of venous thromboembolism (VTE) and is part of the Seventh American College of Chest Physicians Confer …
Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism.
Kucher N, Boekstegers P, Müller OJ, Kupatt C, Beyer-Westendorf J, Heitzer T, Tebbe U, Horstkotte J, Müller R, Blessing E, Greif M, Lange P, Hoffmann RT, Werth S, Barmeyer A, Härtel D, Grünwald H, Empen K, Baumgartner I. Kucher N, et al. Circulation. 2014 Jan 28;129(4):479-86. doi: 10.1161/CIRCULATIONAHA.113.005544. Epub 2013 Nov 13. Circulation. 2014. PMID: 24226805 Clinical Trial.
METHODS AND RESULTS: Fifty-nine patients (6314 years) with acute main or lower lobe pulmonary embolism and echocardiographic RV to left ventricular dimension (RV/LV) ratio 1.0 were randomized to receive unfractionated heparin and an USAT regimen of 10 to 20 m …
METHODS AND RESULTS: Fifty-nine patients (6314 years) with acute main or lower lobe pulmonary embolism and echocardiographic R …
Ultrasound-facilitated, catheter-directed thrombolysis vs anticoagulation alone for acute intermediate-high-risk pulmonary embolism: Rationale and design of the HI-PEITHO study.
Klok FA, Piazza G, Sharp ASP, Ní Ainle F, Jaff MR, Chauhan N, Patel B, Barco S, Goldhaber SZ, Kucher N, Lang IM, Schmidtmann I, Sterling KM, Becker D, Martin N, Rosenfield K, Konstantinides SV. Klok FA, et al. Am Heart J. 2022 Sep;251:43-53. doi: 10.1016/j.ahj.2022.05.011. Epub 2022 May 16. Am Heart J. 2022. PMID: 35588898 Free article. Clinical Trial.
BACKGROUND: Due to the bleeding risk of full-dose systemic thrombolysis and the lack of major trials focusing on the clinical benefits of catheter-directed treatment, heparin antiocoagulation remains the standard of care for patients with intermediate-high-risk pulmonar …
BACKGROUND: Due to the bleeding risk of full-dose systemic thrombolysis and the lack of major trials focusing on the clinical benefits of ca …
620 results